Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05170425 · ClinicalTrials.gov registry record
LAMBDA 002 (Lung Registry) Study
A clinical trial of Lung Transplant Rejection, sponsored by Natera.
- Active
- Registry status
- 154
- Enrollment target
- 11
- Study locations
NCT05170425 is a study of Lung Transplant Rejection that is active but no longer recruiting, run by Natera. The registered enrollment target is 154 participants, below the 635-participant average among 6 other Lung Transplant Rejection trials with a reported enrollment target (76% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT05170425, a study of Lung Transplant Rejection, is active but no longer recruiting, sponsored by Natera.
- ACTIVE NOT RECRUITING
- Registry status
- 154 participants
- Enrollment target
- 11
- Study locations
Study Summary
The LAMBDA 002 registry study is an observational, longitudinal, multi-center study observing patients undergoing lung transplant.
Conditions Studied
Interventions
- DEVICE Prospera
Study Locations (11)
Texas
- UT Southwestern Medical Center - Dallas
- Baylor College of Medicine Medical Center - Houston
- Houston Methodist Hospital - Houston
California
- Cedars-Sinai Medical Center - California City
Illinois
- Northwestern Memorial Hospital - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
Michigan
- Corewell Health - Grand Rapids
Missouri
- Washington University School of Medicine - St Louis
New York
- Columbia University Irving Medical Center - New York
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2027-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05170425
The ClinicalTrials.gov registry entry for NCT05170425 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 635-participant average among 6 other Lung Transplant Rejection trials with a reported enrollment target (76% lower). The listed sponsor is Natera, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Transplant Rejection appearing as the primary indexed condition, and to 1 intervention - of which Prospera is the first listed.
NCT05170425 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Texas, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT05170425 about?
NCT05170425 is a clinical study titled "LAMBDA 002 (Lung Registry) Study". The LAMBDA 002 registry study is an observational, longitudinal, multi-center study observing patients undergoing lung transplant.
What is the current status of trial NCT05170425?
This trial is currently active not recruiting. The enrollment target is 154 participants. The study started on 2022-11-04. Estimated completion is 2027-05.
What conditions does trial NCT05170425 study?
This clinical trial studies the following conditions: Lung Transplant Rejection.
What interventions are being tested in trial NCT05170425?
The interventions under investigation include: Prospera (DEVICE).
Who is sponsoring clinical trial NCT05170425?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05170425 being conducted?
This trial has 11 study locations across California, Illinois, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
RECRUITING
-
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
RECRUITING
-
Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection
RECRUITING · Phase 2
-
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
RECRUITING · Phase 3
-
Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients
RECRUITING · NA
-
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.